Some four months after the White House inked the last of its expected drug pricing deals with 17 of the industry’s top ...
CDMO Lonza is strengthening its market leadership with a newly created role that puts seasoned exec Samanta Cimitan, Ph.D., ...
In a deal that will end intellectual property claims in five countries, including one before the International Trade ...
Late August has been rough for IV solution makers as B. Braun added to its recall tally once more, building on Baxter’s three recalls of similar products in the same time frame. | Late August has been ...
Jazz Pharmaceuticals has added a second overall survival win to Ziihera’s cap, bolstering the bispecific’s claim as the new ...
These are heady days for PharmaEssentia, a biotech that got its start 23 years ago in Taiwan, went public 10 years later and ...
By Alicia Cowley, MD, MBA, Medical Director, Phreesia Network Solutions | Endemic media and broad reach each do half the job.
In its release on the CARDIO-TTRansform data, the ESC echoed AZ and Ionis’ point that Wainua suppressed circulating serum TTR ...
Mimrylo marks the second FDA new drug approval that Takeda has secured since CEO Julie Kim officially took the reins in June ...
In their high-profile competition in the diabetes and obesity markets, Eli Lilly has proven adept in playing catch up with ...
As Fierce Pharma Week approaches, the Fierce Pharma Marketing team is taking stock of some of the biggest trends reshaping ...
Biogen’s late-stage lupus candidates may not have crossed the FDA finish line yet, but the company has already hit the ground ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results